Finerenone in Chronic Kidney Disease and Type 2 Diabetes

Clinical Effects

• Finerenone reduces albuminuria in patients with type 2 diabetes and chronic kidney disease 1
• It provides modest blood pressure lowering effects (2-3 mmHg systolic) 2
• Finerenone significantly reduces the risk of kidney failure progression (HR: 0.82, 95% CI: 0.73-0.93) 1
• It also reduces cardiovascular events including death from cardiovascular causes, nonfatal MI, nonfatal stroke, and hospitalization for heart failure 1

Safety and Monitoring

• While finerenone can cause hyperkalemia (14% vs. 6.9% with placebo), the risk of severe hyperkalemia requiring drug discontinuation is relatively low (1.7% vs. 0.6%) 1
• No deaths due to hyperkalemia were reported in clinical trials over 3 years of follow-up 1
• Finerenone can be used in patients with reduced kidney function (eGFR ≥25 ml/min/1.73m²) with appropriate monitoring 3

Clinical Applications

• Finerenone is indicated for patients with type 2 diabetes and chronic kidney disease with persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated doses of renin-angiotensin system inhibitors 1, 3
• It should be initiated at 10 mg daily for patients with eGFR 25-60 ml/min/1.73m² and 20 mg daily for those with eGFR >60 ml/min/1.73m² 3
• Serum potassium should be <4.8 mmol/L before initiation and monitored regularly during treatment 3

Therapeutic Positioning

• Current guidelines position finerenone as an "additional risk-based therapy" for patients with persistent albuminuria despite standard treatment 4